Literature DB >> 16456803

[HLA-A, B, DRB1 gene polymorphism of Beijing population was studied by high-resolution polymerase chain reaction sequence-based typing].

Ya-jun Deng1, Guang Yang, Dong-ying Wu, Song-nian Hu, Sheng-bin Li, Jun Zhu, Bo-feng Zhu, Yao Liu.   

Abstract

OBJECTIVE: To investigate the gene polymorphism of human leukocyte antigen (HLA)-A, B, DRB1 loci in the population of Beijing region, and research on the application feasibility of polymerase chain reaction sequence-based typing (PCR-SBT) method.
METHODS: PCR-SBT method was applied to determine HLA- A, B, DRB1 genotypes of 618 unrelated healthy individuals of Beijing region.
RESULTS: A total of 84 different alleles and 199 genotypes of HLA-A, 143 alleles and 366 genotypes of HLA-B, 122 alleles and 286 genotypes of HLA-DRB1 were detected.
CONCLUSION: The results showed the characteristics of HLA-A, B, DRB1 distributions, and provided more comprehensive and accurate gene data that may serve as normal reference values for all of Beijing people.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456803

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi        ISSN: 1003-9406


  3 in total

1.  Allele polymorphism and haplotype diversity of HLA-A, -B and -DRB1 loci in sequence-based typing for Chinese Uyghur ethnic group.

Authors:  Chun-mei Shen; Bo-feng Zhu; Ya-jun Deng; Shi-hui Ye; Jiang-wei Yan; Guang Yang; Hong-dan Wang; Hai-xia Qin; Qi-zhao Huang; Jing-Jing Zhang
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

2.  HLA-DRB1 alleles are associated with the susceptibility to sporadic Parkinson's disease in Chinese Han population.

Authors:  Congcong Sun; Lei Wei; Feifei Luo; Yi Li; Jiaobiao Li; Feiqi Zhu; Ping Kang; Rensi Xu; Lulu Xiao; Zhuolin Liu; Pingyi Xu
Journal:  PLoS One       Date:  2012-11-06       Impact factor: 3.240

3.  Rheumatic diseases in China.

Authors:  Qing Yu Zeng; Ren Chen; John Darmawan; Zheng Yu Xiao; Su Biao Chen; Richard Wigley; Shun Le Chen; Nai Zheng Zhang
Journal:  Arthritis Res Ther       Date:  2008-01-31       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.